EVMN Evommune, Inc.
Distress ·
The 121-patient trial failed at every dose. Evommune will keep testing EVO756 in migraine, move EVO301 forward and says cash lasts into 2029, a forecast that rests on revised plans.
Evommune's chief financial officer disclosed a purchase that matches a May sale under the short-swing rule, and agreed to pay the company $10,160.
Evommune's $125 million private placement was followed by a failed atopic dermatitis trial; the company says its 2026 raise brought net proceeds of $117.2 million.
Evommune sold 9,375,000 shares at $16.00 in its New York Stock Exchange listing, with a 30-day option on 1,406,250 more. Its most advanced drug's efficacy data come from a small Phase 2 study in a different condition than the one it is pursuing.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $13.0 million | $7.0 million |
| Research and development | $74.0 million | $64.2 million |
| Net income (loss) | -$68.9 million | -$66.8 million |
| Cash from operations | -$76.4 million | -$58.2 million |
| Cash and equivalents | $44.1 million | $16.3 million |
| Short-term investments | $105.1 million | $55.8 million |
Our latest story on this, dated Nov 7, 2025: "Evommune closes NYSE IPO of 10.8 million shares at $16, nets $157.0 million". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Feb 12, 2026: "Evommune sells $125 million of stock privately at $27.88 a share". The story links the filing or release it is based on. Read the story.
Evommune, Inc. trades under the ticker EVMN on NYSE.
Evommune, Inc. is listed on NYSE.
The SEC Central Index Key (CIK) for Evommune, Inc. is 2044725. Its filings are on SEC EDGAR.
36,292,113 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Evommune, Inc. under United States.
Our directory classifies Evommune, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Evommune, Inc. is US30054Y1073.
aibio.space lists Evommune, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
$13.0 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Evommune, Inc. reported a net loss of $68.9 million for the fiscal year ended Dec 31, 2025, and used $76.4 million of cash in operations, per its annual report to the SEC.
$74.0 million in the fiscal year ended Dec 31, 2025, per its annual report.
$200.8 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
After top-line Phase 2b results, Evommune said it would stop developing EVO756 for atopic dermatitis and expects cash and investments to fund operations into 2029 under its revised plans. Source
Evommune filed the selling-stockholder resale prospectus; issuer proceeds from resales were excluded. Source
Evommune filed a Form S-1 for resale registration; this is a filing date rather than a verified effectiveness date. Source
The annual report said management plans alleviated earlier substantial doubt. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Evommune agreed a common-stock private placement with approximately $125 million estimated gross proceeds. Source
The initial public offering closed, alongside charter and bylaw amendments. Source
Filed a final prospectus for a securities offering. SEC Form 424B4. Source
Evommune completed a pre-IPO one-for-8.5180 common-stock reverse split. Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Evommune issued the second tranche of Series C preferred shares for $65.3 million gross. Source
The company reported $288.0 million in total cash, cash equivalents and investments at 2026-06-30. This includes long-term investments and is not a cash-only figure. Source
A later filing said revised business plans were expected to be funded into 2029. The estimate is conditional and does not give a precise exhaustion date. Source
The annual report said management implemented plans that alleviated earlier substantial doubt. Source
It completed a one-for-8.5180 reverse split before the IPO. No exchange-deficiency rationale is verified for that action. Source
The latest quarterly cover identifies the New York Stock Exchange and the EVMN symbol. No open deficiency has been verified in this research. Source
It agreed a common-stock placement at $27.88 per share. Later periodic reports disclose the related proceeds. Source
The prospectus says the issuer will receive no proceeds from the covered shareholder resales. Source
The latest annual audit is signed by BDO USA, P.C. Source
A Form 4 reports a purchase by chief financial officer Kyle Carver and his agreement to pay the issuer the matched short-swing profit of $10,160. It does not prove the payment was received. Source
The latest quarterly filing states no material legal proceeding was pending or threatened at its reporting date. This research does not certify absence across every court or later date. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio